We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$819M
AUM Growth
+$123M
(+18%)
Cap. Flow
+$101M
Cap. Flow
% of AUM
12.29%
Top 10 Holdings %
Top 10 Hldgs %
9.75%
Holding
710
New
168
Increased
162
Reduced
95
Closed
285
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$9.74M |
| 2 |
McDonald's
MCD
|
+$8.2M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$8.03M |
| 4 |
AGN
Allergan plc
AGN
|
+$7.37M |
| 5 |
Henry Schein
HSIC
|
+$6.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$7.17M |
| 2 |
Lam Research
LRCX
|
+$6.99M |
| 3 |
Electronic Arts
EA
|
+$6.98M |
| 4 |
MBLY
Mobileye N.V.
MBLY
|
+$6.79M |
| 5 |
Hilton Worldwide
HLT
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.19% |
| 2 | Technology | 15.05% |
| 3 | Consumer Discretionary | 14.44% |
| 4 | Financials | 11.43% |
| 5 | Consumer Staples | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSRA
226
DELISTED
CSRA Inc.
CSRA
| $1.18M | 0.14% |
36,500
-23,900
| -40% | -$770K |
|
|
ESPR
227
DELISTED
Esperion Therapeutics
ESPR
| $1.17M | 0.14% |
23,398
+21,531
| +1,153% | +$1.04M |
|
228
Assured Guaranty
AGO
$3.79B
| $1.17M | 0.14% |
+31,000
| New | +$1.33M |
|
|
TRCO
229
DELISTED
TRIBUNE MEDIA COMPANY CLASS A
TRCO
| $1.17M | 0.14% |
28,586
-50,800
| -64% | -$2.06M |
|
230
Pfizer
PFE
$144B
| $1.16M | 0.14% |
34,197
+34,150
| +72,660% | +$1.1M |
|
231
Sabre
SABR
$743M
| $1.16M | 0.14% |
63,826
+19,600
| +44% | +$380K |
|
|
OPTU
232
Optimum Communications Inc
OPTU
$298M
| $1.15M | 0.14% |
+42,200
| New | +$1.29M |
|
233
Eagle Materials
EXP
$6.86B
| $1.15M | 0.14% |
10,800
+8,500
| +370% | +$811K |
|
|
GRA
234
DELISTED
W.R. Grace & Co.
GRA
| $1.15M | 0.14% |
15,900
+8,500
| +115% | +$600K |
|
|
OA
235
DELISTED
Orbital ATK, Inc.
OA
| $1.15M | 0.14% |
+8,596
| New | +$943K |
|
236
Novartis
NVS
$304B
| $1.13M | 0.14% |
14,693
+10,937
| +291% | +$826K |
|
237
Coca-Cola Europacific Partners
CCEP
$49.3B
| $1.12M | 0.14% |
27,000
-18,600
| -41% | -$789K |
|
|
NDRM
238
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.12M | 0.14% |
+28,700
| New | +$1.06M |
|
239
Texas Roadhouse
TXRH
$13.5B
| $1.11M | 0.14% |
+22,512
| New | +$1.1M |
|
240
Norwegian Cruise Line
NCLH
$9.74B
| $1.1M | 0.13% |
20,375
+12,200
| +149% | +$682K |
|
241
Mohawk Industries
MHK
$7.14B
| $1.09M | 0.13% |
4,400
+4,100
| +1,367% | +$1.02M |
|
242
Generac Holdings
GNRC
$11.5B
| $1.07M | 0.13% |
+23,400
| New | +$920K |
|
|
ATVI
243
DELISTED
Activision Blizzard
ATVI
| $1.07M | 0.13% |
16,600
-15,700
| -49% | -$979K |
|
244
Maximus
MMS
$3.31B
| $1.06M | 0.13% |
16,400
+10,300
| +169% | +$631K |
|
|
JWN
245
DELISTED
Nordstrom
JWN
| $1.04M | 0.13% |
+22,013
| New | +$1.02M |
|
246
Nexstar Media Group
NXST
$5.92B
| $1.03M | 0.13% |
16,500
+13,500
| +450% | +$833K |
|
|
MRO
247
DELISTED
Marathon Oil Corporation
MRO
| $1.02M | 0.12% |
75,201
+12,249
| +19% | +$145K |
|
248
Yum China
YUMC
$15.6B
| $1.02M | 0.12% |
25,466
-83,234
| -77% | -$3.1M |
|
249
Opko Health
OPK
$1.25B
| $1M | 0.12% |
+146,500
| New | +$924K |
|
|
KEM
250
DELISTED
KEMET Corporation
KEM
| $993K | 0.12% |
+47,000
| New | +$888K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Seven Eight Capital held 710 positions worth $819M, up 18% from $696M the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Seven Eight Capital deployed $101M of net new capital in Q3 2017, opening 168 new positions and adding to 162 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 90,387 shares worth $5.25M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 10% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Constellation Brands, an estimated $6.37M trimmed.
- Seven Eight Capital's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 90,387 shares worth $5.25M.
- Seven Eight Capital added most to McDonald's in Q3 2017, an estimated $8.2M increase.
- Seven Eight Capital's biggest Q3 2017 reduction was Constellation Brands, cutting an estimated $6.37M.
- Seven Eight Capital fully exited Nike in Q3 2017, selling an estimated $7.17M.
- Seven Eight Capital's ten largest holdings make up 9.8% of its $819M portfolio in Q3 2017.
- Seven Eight Capital opened 168 new positions and closed 285 in Q3 2017.
- Seven Eight Capital's portfolio value rose 18% quarter-over-quarter to $819M.
Based on Seven Eight Capital's 13F filing for Q3 2017, filed 16 Oct 2017.